T. Rowe Price Associates’s Elanco Animal Health ELAN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $34M | Sell |
1,381,660
-1,819,830
| -57% | -$42.1M | ﹤0.01% | 999 |
|
|
2026
Q1 | $76.6M | Buy |
3,201,490
+404,737
| +14% | +$9.89M | 0.01% | 669 |
|
|
2025
Q4 | $63.3M | Buy |
2,796,753
+2,378,455
| +569% | +$51.8M | 0.01% | 739 |
|
|
2025
Q3 | $8.43M | Buy |
418,298
+23,100
| +6% | +$387K | ﹤0.01% | 1269 |
|
|
2025
Q2 | $5.64M | Sell |
395,198
-6,717
| -2% | -$78.5K | ﹤0.01% | 1241 |
|
|
2025
Q1 | $4.22M | Sell |
401,915
-154,557
| -28% | -$1.75M | ﹤0.01% | 1299 |
|
|
2024
Q4 | $6.74M | Sell |
556,472
-2,479,034
| -82% | -$32.4M | ﹤0.01% | 1212 |
|
|
2024
Q3 | $44.6M | Sell |
3,035,506
-25,032,216
| -89% | -$349M | 0.01% | 785 |
|
|
2024
Q2 | $405M | Buy |
28,067,722
+5,928,704
| +27% | +$94.7M | 0.05% | 306 |
|
|
2024
Q1 | $360M | Buy |
22,139,018
+852,281
| +4% | +$13.3M | 0.04% | 323 |
|
|
2023
Q4 | $317M | Buy |
21,286,737
+1,365,731
| +7% | +$15.5M | 0.04% | 330 |
|
|
2023
Q3 | $224M | Buy |
19,921,006
+2,494,084
| +14% | +$29M | 0.03% | 370 |
|
|
2023
Q2 | $175M | Buy |
17,426,922
+105,179
| +0.6% | +$976K | 0.02% | 414 |
|
|
2023
Q1 | $163M | Sell |
17,321,743
-1,329,896
| -7% | -$15.7M | 0.02% | 415 |
|
|
2022
Q4 | $228M | Sell |
18,651,639
-8,379,249
| -31% | -$104M | 0.04% | 352 |
|
|
2022
Q3 | $335M | Buy |
27,030,888
+4,872,640
| +22% | +$85.2M | 0.06% | 278 |
|
|
2022
Q2 | $435M | Sell |
22,158,248
-12,354,858
| -36% | -$292M | 0.06% | 321 |
|
|
2022
Q1 | $900M | Buy |
34,513,106
+48,052
| +0.1% | +$1.28M | 0.09% | 224 |
|
|
2021
Q4 | $978M | Sell |
34,465,054
-12,502,789
| -27% | -$389M | 0.09% | 229 |
|
|
2021
Q3 | $1.5B | Buy |
46,967,843
+188,117
| +0.4% | +$6.31M | 0.14% | 147 |
|
|
2021
Q2 | $1.62B | Buy |
46,779,726
+5,006,187
| +12% | +$165M | 0.15% | 146 |
|
|
2021
Q1 | $1.23B | Buy |
41,773,539
+332,959
| +0.8% | +$10.2M | 0.12% | 186 |
|
|
2020
Q4 | $1.27B | Buy |
41,440,580
+442,967
| +1% | +$13.5M | 0.13% | 169 |
|
|
2020
Q3 | $1.15B | Sell |
40,997,613
-4,882,365
| -11% | -$124M | 0.13% | 164 |
|
|
2020
Q2 | $984M | Sell |
45,879,978
-784,642
| -2% | -$17.3M | 0.12% | 173 |
|
|
2020
Q1 | $1.04B | Buy |
46,664,620
+13,279,963
| +40% | +$364M | 0.17% | 133 |
|
|
2019
Q4 | $983M | Sell |
33,384,657
-3,831,422
| -10% | -$104M | 0.13% | 175 |
|
|
2019
Q3 | $990M | Sell |
37,216,079
-5,116,462
| -12% | -$153M | 0.14% | 161 |
|
|
2019
Q2 | $1.43B | Buy |
42,332,541
+3,653,638
| +9% | +$119M | 0.2% | 121 |
|
|
2019
Q1 | $1.24B | Buy |
38,678,903
+35,844,944
| +1,265% | +$1.1B | 0.18% | 127 |
|
|
2018
Q4 | $89.4M | Buy |
2,833,959
+16,433
| +0.6% | +$538K | 0.02% | 636 |
|
|
2018
Q3 | $98.3M | Buy |
+2,817,526
| New | +$99.1M | 0.01% | 675 |
|
Other funds holding ELAN
T. Rowe Price Associates's ELAN Position: Q2 2026 in Review
T. Rowe Price Associates reduced its Elanco Animal Health (ELAN) stake by 57% in Q2 2026, selling an estimated $42.1M and leaving 1,381,660 shares worth $34M. The position accounts for ﹤0.01% of the portfolio, ranked #999.
T. Rowe Price Associates first reported a position in ELAN in Q3 2018 and has held it in 32 quarters since. The position peaked at $1.62B in Q2 2021. 521 funds tracked by Wall St. Rank hold ELAN as of Q2 2026.
- T. Rowe Price Associates held 1,381,660 shares of Elanco Animal Health worth $34M as of Q2 2026.
- T. Rowe Price Associates sold 1,819,830 Elanco Animal Health shares in Q2 2026, an estimated $42.1M.
- Elanco Animal Health made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #999 holding.
- T. Rowe Price Associates first reported a position in Elanco Animal Health in Q3 2018 and has held it in 32 quarters since.
- T. Rowe Price Associates's Elanco Animal Health position peaked at $1.62B in Q2 2021.
- 521 funds tracked by Wall St. Rank held Elanco Animal Health as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.